Navigation Links
Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
Date:8/22/2007

A nanoparticle drug delivery system designed for brain tumor therapy has shown promising tumor cell selectivity in a novel cell culture model devised by University of Nottingham scientists. The project, conducted jointly in the Schools of Pharmacy, Biomedical Sciences and Human Development, will be featured in the September issue of the Experimental Biology and Medicine.

Therapy for brain cancers is particularly difficult for a number of reasons, including getting sufficient drug to the tumor and selectivity of drug action. We are working on a number of new therapeutic approaches using nanoparticle drug delivery systems explained Dr Martin Garnett, Associate Professor of drug delivery at the School of Pharmacy, however, understanding and developing these systems requires suitable models for their evaluation.

The nanoparticles used in this study were prepared from a novel biodegradable polymer poly(glycerol adipate). The polymer has been further modified to enhance incorporation of drugs and make the nanoparticles more effective.

The interaction of tumor cells with brain cells varies between different tumors and different locations within the brain explained Dr Terence Parker, Associate Professor in the School of Biomedical Sciences. Using 3-dimensional culture models is therefore important in ensuring that the behavior of cells in culture is similar to that seen in real life.

The work was mainly carried out by graduate student Weina Meng who formulated the fluorescently labeled nanoparticles and studied them in a variety of tumor and brain cell cultures. Her early studies showed faster uptake of nanoparticles into tumor cell cultures than normal brain cell cultures grown separately. This selectivity was only seen in 3-dimensional cultures and was the driving force to develop a more complex and representative model.

Tumor cell aggregates have been used as cell culture models of cancer cells for many years. Similarly thin brain slices from newborn rats can be cultured for weeks and are an important tool in brain biology. In the cell co-culture model now reported, these two techniques have been brought together for the first time. Brain tumor cell aggregates were labeled with fluorescent iron microparticles and grown on normal newborn rat-brain tissue slices. The double cell labeling technique allowed investigation of tumor cell invasion into brain tissue by either fluorescence or electron microscopy from the same samples. Using these techniques the tumor aggregates were found to invade the brain slices in a similar manner to tumors in the body. Having developed the model then the tumor selective uptake of nanoparticles was demonstrated in the co-culture.

The collaboration on this project has been nurtured by Professor David Walker of the School of Human Development who co-founded the Childrens Brain Tumor Research Group at Nottingham. Understanding the biology of tumors is important if we are to develop effective new treatments said Professor Walker. This work demonstrates how close co-operation between disciplines can help to push forward ideas which could lead to new clinical therapies.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees with Professor Walker. Dr. Goodman stated The convergence of cancer cell biology and nanoscience, exemplified by this study, holds great promise for the future of brain tumor therapy. Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.


'/>"/>

Contact: Dr. Martin Garnett
martin.garnett@nottingham.ac.uk
44-011-595-15045
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
7. Discovery Could Lead To Novel Approaches In HIV Treatment
8. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
9. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
10. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
11. GeneNotes - A novel information management software for biologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/20/2017)... ... June 20, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, announces launch of its new Surge(TM) Discovery service ... CEO of GigaGen, will present on Surge at the conference. , Surge is ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been ... One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today ... is Kati Abraham , who is well known in the industry and brings ...
Breaking Biology Technology: